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1
NEUROPATHOLOGICAL DIAGNOSIS OF ALZHEIMER’S DISEASE: THE
RELATIONSHIP BETWEEN POSTMORTEM ASSESSMENT, COGNTIVE AND
FUNCTIONAL STATUS IN CENTENARIANS
Specific Aims
Neuritic plaques (NP) and neurofibrillary tangles (NFT) are the two major
hallmarks of Alzheimer’s Disease (AD) found within the brain and detectable only at
autopsy (Cutler & Sramek, 1996). The presence of these lesions, in conjunction with a
clinical history of dementia, is required in order to arrive at a definitive diagnosis of AD
(McKhann, et al., 1984). Several sets of neuropathological criteria have been proposed
and used for AD diagnosis during postmortem neuropathological assessment, although
there has been little consensus regarding which protocol is the best for purposes of
research. In addition, few studies have applied these protocols to neuropathological
assessment of AD in the oldest old. A better understanding of the relative merits of
different neuropathological criteria among centenarians, the “oldest old,” is essential to
answering the question of whether or not AD is an inevitable consequence of aging.
For this study, we examined a sample of centenarians, all of whom received
postmortem assessments using four different neuropathological criteria that are presented
in Table 1. These criteria include: 1) Khatchaturian Criteria (Khatchaturian, 1985); 2)
Consortium to Establish a Registry of Alzheimer’s Disease (CERAD) criteria (Mirra,
Heyman, McKeel et al., 1991); 3) Braak and Braak Criteria (Braak & Braak, 1991); and
4) National Institute on Aging- Reagan Criteria (NIA-R; Hyman & Trojanowski, 1998).
We investigated the relationship between neuropathological severity level and
performance on measures of neuropsychological and functional performance to gain a
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neuropsychological measures were used, as detailed in Table 2. Mini-Mental State
Examination (MMSE; (Cockrell & Folstein, 1988) scores were used to measure
antemortem global cognitive functioning. To assess more specific cognitive domains
frequently impaired in patients with AD, a measure of executive functioning, the
Behavioral Dyscontol Scale (BDS), and a measure of memory, the Fuld Object Memory
Evaluation (FOME) were used.

Finally, to investigate the possibility that

neuropathological burden translates into impairments of daily living skills, the Direct
Assessment of Functional Status (DAFS) was used. The following specific aims will be
accomplished in this study:
Specific Aim 1
The goal of this aim was to determine whether the four different
neuropathological assessment protocols would yield conflicting or consistent diagnostic
information regarding AD severity.
Protocols to guide the neuropathological diagnosis of AD were first proposed by
Khachaturian in 1985. Since that time, new protocols have been developed, with the
goal of improving the accuracy of postmortem AD diagnosis. Most recently, the NIA-R
criteria were published in 1997. However, no protocol has been uniformly adopted by
neuropathologists (Geddes et al., 1997). As a result, the existence of multiple protocols
creates a situation where a diagnosis of AD may vary, contingent upon the protocol used
for assessment.
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As indicated in Table 3, each protocol uses different criteria for assessing the
relevance of neuropathological markers and the extent and location of neuropathological
burden. Therefore, we hypothesized that discrepancies among criteria would be apparent
when classifying severity of AD-related neuropathology in centenarians. Specifically,
since both Khachaturian criteria and CERAD criteria quantify only NPs, we expected
these protocols to differ from Braak and Braak criteria, which quantifies only NFTs.
Also, since Khachaturian, CERAD, and Braak and Braak criteria measure only one ADtype brain lesion for diagnosis, we expected that these three criteria would differ from
NIA-R criteria, which measures two AD-type brain lesions for diagnosis.
Specific Aim 2
The goal of this aim was to investigate the relationship between disease
progression and the extent and type of cognitive and functional impairment in a sample
of centenarians.
Neuropathological criteria for AD have been developed using the “younger old”
(Savva, et al., 2009). Even those investigations claiming to include “older” brains in their
analysis regularly used samples between the ages of 70-75 years (Prohovinik, et al.,
2006). In general, the current literature is heavily skewed towards younger patients, and
very little is known about the brain changes that accompany advanced or extreme age
(Skoog, Nilsson, Palmertz, Andreasson, & Svanborg, 1993).

However, several

neuropathological indicators of AD in the oldest-old have been reported to be divergent
from those found in younger brains, in both distribution and concentration of lesions
(Jellinger, 2008). Arguably, the available protocols may have differential utilities for
diagnosing AD in oldest old, and it is critical to examine how current post-mortem
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assessments of AD relate to the ante-mortem clinical status of dementia.

By using a

sample of centenarians, our study will attempt to elucidate clinical correlates of the
neuropathological severity criteria associated with the different classification systems.
Our primary goal was to demonstrate how each neuropathological severity grading
system relates to neuropsychological test performance in the oldest old. A better
understanding of the relationship between each neuropathological severity grading
systems and neuropsychological test performance in centenarians would identify how
specific types of neuropathology impact discrete cognitive abilities in late life.
1. We hypothesized that severity grading criteria from diagnostic protocols that
rely on NFTs as a neuropathological indicator of AD diagnosis would be significantly
related to cognitive impairment, whereas severity gradings from protocols that
emphasize SPs would not be related to cognitive impairment.

Previous evidence

indicates that cognitive impairment correlates more strongly with the quantity of NFTs
than with SPs in individuals with AD. Therefore, the strongest relationships between
neuropathological severity grade and neuropsychological test performance are expected
for the NIA-R and Braak & Braak criteria, both of which quantify the presence of NFTs.
In

contrast,

relationships

between

neuropathological

severity

grade

and

neuropsychological test performance would not be expected for CERAD and
Khachaturian criteria, given that both sets of criteria emphasize the presence of SP.
2. It is also hypothesized that different stages of disease progression will yield
distinct neuropsychological impairments. For example, it is well-known that patients in
the earlier stages of AD show substantial deficits in memory, and as the disease
progresses, patients begin to show additional deficits in executive function, judgment,
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visuospatial capacities and language (Braak, et al., 1999). For this aim, we will
investigate the association between cognitive status at the time of study entry and
neuropathological severity at death, according to NIA-R criteria. This aim may help to
elucidate which cognitive domains are most vulnerable across the stages of disease
progression.

In addition, we will also explore the possibility that certain cognitive

domains might be spared, even during the most advanced stages of AD.
Background and Significance
A Brief History of AD
During a 1906 lecture to German psychiatrists, Alois Alzheimer described the
case of Auguste D., a patient he treated while working as a physician in the Frankfurt
Asylum (Graeber, 1999). Prior to her death at the age of 55, Auguste D. experienced a
wide range of incapacitating symptoms, including progressive memory decline,
paranoia, delusions, cognitive impairments and a loss of language abilities (Selkoe,
2001). After a postmortem examination, Alzheimer discovered an unusual pattern of
neuropathology in Auguste D.’s brain, including the presence of both senile plaques (SP)
and neurofibrillary tangles (NFT). Although plaques had been described previously,
Alzheimer was the first to identify tangle pathology and assert the connection between
these abnormalities and memory deterioration (Zec, 1993). Later, in 1910, Emil Kraplin
assigned Alzheimer’s name to the newly discovered dementia that included both clinical
symptoms and specific brain changes (Cutler & Sramek, 1996).
A century later, Alzheimer’s blending of astute clinical observations and
systematic neuropathological examination continues to be the model for Alzheimer’s
disease (AD) assessment (Khachaturian, 2000). Presently, a definite diagnosis of AD
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necessitates that the patient have both a clinical history of dementia and evidence of
sufficient numbers of NFTs and SPs at the time of autopsy (Geddes et al., 1997).
Neuropathology in AD
Plaques. Senile plaques (also known as neuritic or amyloid plaques) are the
product of dendritic and axonal damage, resulting from to amyloid deposits in the
extracellular space (Selkoe, 2001). Two broad types of plaques can be categorized:
diffuse and focal. Diffuse plaques involve neurons with normal axons and have been
found in large numbers of patients with no clinical signs of dementia. Thus, it has been
concluded that these lesions may not be directly harmful (Dickson, Crystal, Mattiace,
Masur, Blau, Davies, Yen & Arronson, 1992). Focal, or neuritic plaques consist of
abnormal axons, surrounded by a core of amyloid (Cutler & Sramek, 1996).
The core of the senile plaque contains several proteins, but the most abundant is a
small peptide known as β-amyloid or a-beta (Aβ) that aggregates into fibrils (Anderton,
2002). Aβ is a normal cellular component and is produced in low concentrations, most
likely as a waste product. However, if there is an imbalance between the production and
removal of Aβ, an accumulation occurs (Duyckaerts, Delatour & Potier, 2009).

This

accumulation is thought to contribute to neuronal death or dysfunction through a series
of events that includes the production of free radicals, mitochondrial oxidative damage,
and an overall inflammatory response (Schindowski, Belarbi, & BuÈe, 2008).
Neurofibrillary Tangles.

Neurofibrillary tangles are present within neurons

and are a consequence of an alteration of the tau protein (Kidd, 2008). Tau proteins are
associated with the microtubules of the cell and are abundant in the central nervous
system, where they are expressed most often within axons (Cleveland, Hwo, &
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Kirschner, 1977, (Weingarten, Lockwood, Hwo, & Kirschner, 1975). There are several
well-understood functions of the tau protein, but most notably, tau binds to and stabilizes
microtubules (MT) and allows for MT polymerization (Weingarten, et al., 1975). When
using light microscopy, the neurofibrillary lesions of the AD brain can be stained with
anti-tau antibodies, revealing paired helical filaments (PHFs) and straight filaments,
composed mostly of abnormally hyperphosphorylated tau proteins (Lee, Goedert &
Trojanowski, 2001). The cause of these filaments is unclear, but it is possible that the
hyperphosphororylation of the tau separates it from the MT, thus increasing the amount
of unbound tau in the cell. Hyperphosphororylation is thought to be an early event that
transforms tau from its primary soluble form, to an insoluble form. In neurons affected
by PHF, the cytoskeleton of the MT and neurofilaments disappear, leading to neuronal
death (Anderton, 1997).
Neuropathological Quantification
In order to establish a definitive diagnosis of Alzheimer’s Disease,
neuropathologists must examine the neocortex, entorhinal cortex, hippocampus, and
amygdala for evidence of SPs and/or NFTs. However, the process of making a diagnosis
of AD is not without subjectivity and inconsistency on the part of the neuropathologist,
leading to efforts to establish reliable diagnostic criteria (Markesbery, 1997).
Khachaturian Criteria. In 1985 the National Institute on Aging, the National
Institute of Neurological and Communicative Disorders and Stroke, the National
Institute of Mental Health and the American Association of Retired Persons sponsored a
workshop. A major focus of this workshop was to formulate a research agenda aimed at
delineating the critical issues related to the early and accurate diagnosis of AD, as well
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as to develop recommendations for a more standardized approach to postmortem brain
investigation (Khachaturian, 1985). As a direct result of this meeting, Khachaturian
developed histological guidelines for the identification of AD based on hospital autopsy
of patients with fully developed and clinically obvious signs of the disease (Ng'walali,
Yonemitsu, Kibayash, & Tsunenari, 2002). This approach requires the age-corrected
quantification of neocortical plaques per unit area, with at least 8 neocortical SP
densities per square millimeter for patients 50-65; 10 or more for patients 66-77; and 15
or more for patients older than 75 (Giannakopoulos, Hof, Michel, Guimon, & Bouras,
1997). Sections of the frontal, temporal and parietal neocortex are reviewed, in addition
to the amygdala, hippocampus, basal ganglia, cerebellum and the spinal cord
(Markesbery, 1997). Although plaques are either amyloid or neuritic with tau/PHF
positive neurites, the Khachaturian criteria do not provide explicit instructions in regards
to the type of plaque that should be enumerated or the exact brain region that should be
investigated (Jellinger, 1998).
Since the original proposal of the NIA-supported Katchaturian criteria, efforts to
classify pathological features of AD have persisted, and the postmortem diagnosis has
continued to evolve. This evolution is based partially on findings that non-demented
older adults often meet Khatchaturian critieria for AD (Crystal, Dickson, Davies, Masur,
Grober & Lipton, 2000). As a consequence, several groups have since initiated
alternative ways to inform the neuropathological investigation of AD (Wisniewski &
Silverman, 1998).
Braak and Braak. Braak and Braak developed a staging method to rate the
degree and severity of AD disease progression (Kidd, 2008). After the investigation of
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83 autopsied brains, Braak and Braak identified a reliable configuration of
neurofibrillary tangles amassing in cortical and subcortical areas (Newell, Hyman,
Growdon & Hedley-Whyte, 1999). These researchers, unlike Katchaturian, felt that the
presence of β-amyloid did not appropriately differentiate between early and more
advanced cases of AD.

Consequently, their approach focused exclusively on

neurofibrillary alterations in the brain, including the development of neuritic plaques,
neurofibrillary tangles, and neuropil threads (Wisniewski & Silverman, 1997). More
specifically, Braak and Braak proposed that as the disease process progressed, these
markers developed in a predictable sequence, appearing first in the inferotemporal
allocortex via the hippocampus and then spreading to the neocortical association areas
(Braak & Braak, 1991). Six hierarchical levels define Braak and Braak staging. Stages I
and II include few (I) or numerous (II) accumulations of NFT in entorhinal cortex, and
possible rare NFTs in other brain areas. Stages III and IV include greater numbers of
NFTs in the entorhinal cortex, plus the hippocampus, and a few cortical tangles can also
be observed. Finally in Stages V and VI, there is severe involvement of the entorhinal
cortex and the hippocampus and many tangles in the neocortex (Silver, Newell, Brady,
Hedley-White & Perls, 2002).
CERAD Criteria. Formed in 1986, The Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD) is a longitudinal multi-center study that sought to
address the need for a consistent methods of evaluating patients with AD (Gearing, et al.,
1995). In 1991, CERAD responded to observed staining disparities and inter-rater
counting discrepancies amongst laboratories by proposing new criteria. The new criteria
were designed to enhance communication between investigators and to further facilitate
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the merging of data from various medical centers (Jellinger & Bancher, 1998). CERAD
criteria include assessment of neuritic plaques, using a 4-grade scale ranging from none
to frequent (Mirra, 1997). Microscopic sections are required from the hippocampus and
the amygdala, as well as from the frontal, temporal, parietal and occipital neocortex
(Fillenbaum, et al., 2008). These plaque counts are then placed into the context of three
distinct age categories: less than 50, 50-75, and over 75 (Keller, 2006). Finally, agerelated NP scores are integrated with a clinical history of dementia to determine whether
a diagnosis of AD is possible, probable or definite. No examination of NFT distribution
or AD changes in the allocortex is necessary. Furthermore, no standardized description
of NP is provided and there is no differentiation between mild or severe forms of the
disease (Jelinger & Bancher, 1998).
NIA-R Criteria. In 1997, the National Institute on Aging (NIA), in concert with
the Ronald Reagan Institute for the Alzheimer’s Association, suggested a new procedure
for postmortem diagnosis of AD, including an examination of both neuritic plaques and
neurofibrillary tangles (Newell, Hyman, Growdon, & Hedley-Whyte, 1999). After
exclusion of other causes of dementia, the likelihood that AD accounts for dementia is
considered high, intermediate or low according to the frequency of neuritic AD lesions.
lesions are quantified utilizing both the CERAD criteria and Braak staging.

For

example, the diagnosis of high likelihood of AD requires the combination of frequent
neuritic plaques as defined by CERAD criteria, and neurofibrillary tangles in the
neocortex, sufficient to warrant a Braak and Braak stage of V or VI (Hyman, 1998).
This algorithm only considers the classic presentation of AD, which includes both
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plaques and tangles, and thus does not identify other presentations of the disease,
including the plaque-only and the tangle-only subtypes (Jellinger, 2008).

Pathological Brain Changes Associated with Age
Normal Aging.
elderly individuals.

Brain changes and mental decline are commonly found in

An extensive body of research has confirmed that humans

demonstrate an age-related loss of cognitive performance, including deterioration in fluid
reasoning, processing speed, spatial ability and memory (Keller, 2006). In addition,
increased age reliably brings about a reduction in dopaminergic receptors in the brain,
volumetric shrinkage of brain structures, and a reduced density of while matter (Park &
Reuter-Lorenz, 2009). Other universal consequences of aging include granular
degeneration of myelin and axonal dystrophy (Dickson, 2005). These physiological
changes may be related to the cognitive decline that is observed in aging individuals,
which includes reduced abilities in processing speed, working memory, inhibition and
cognitive control (West, 1996).

For example, Park et al. (2002) conducted

neuropsychological assessments on 345 participants, with 48-57 participants represented
in each age decade, including individuals in their 20’s through their 80’s at the time of
death.

This cross-sectional investigation demonstrated gradual age related declines in

cognitive abilities, including working memory, processing speed, and long term
memory. Salthouse (1996) has argued that during normal aging, selective domains of
cognitive abilities may be affected, with executive function and processing speed
showing the greatest vulnerability to age, as compared to other domains.
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Although aging is inevitably associated with alterations in the functional
performance of the brain and shifts in cognitive abilities, major structural changes are
usually minimal and cognitive changes gradual.

Thus, the neuropathological

presentation and dementia experienced by the patient with AD is not considered
“normal” aging and is related to a distinct disease process (Kern & Behl, 2009).
Pathological Aging. Even though the presence of plaques and neurofibrillary
tangles are compulsory for a diagnosis of AD, increasing evidence from autopsy studies
suggests that the brains of healthy elderly individuals also show signs of AD related
neuropathology (Keller, 2006).

The presence of NFTs and SPs in non-demented

subjects has been referred to as “pathological aging” or “pre-symptomatic AD,” and the
true significance of the neuropathological markers in otherwise healthy adults is
unknown. One study found that, depending on the criteria that were used, a number of
older adults with no clinical history of dementia actually possessed neuropathology
sufficient to warrant a diagnosis of AD. Within their dementia-free sample, 11% of
individuals met NIA-Reagan criteria for a diagnosis of intermediate likelihood of AD,
18% met CERAD criteria for possible AD, and 49% met Khachaturian criteria for AD
(Schmitt, et al., 2000). In a similar study utilizing 97 brains of non-demented older
adults, 47% met Khachaturian criteria, 39% met CERAD and NIA-R criteria (with all
levels included), and 27% meeting Braak and Braak Stage III or higher (Price, et al.,
2009).

Another neuropathological investigation using 137 brains of non-demented

elders, autopsied between the ages of 82 and 85 years, reported that 37.3% met NIA-R
criteria for Intermediate/High likelihood of AD (Bennett et al., 2006).
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whether

neuropathological markers of AD represent a distinct disease process, or rather, an
inevitable age related occurrence (Giannakopoulos, et al., 2007). Possibly, the presence
of NFTs and SPs among non-demented older adults indicates a preliminary stage of AD
that is not yet associated with the clinical signs of dementia. Perhaps some individuals
require extensive neuropathology before cell damage reaches levels sufficient to produce
clinical symptoms of AD (Price, et al., 2009).
Neuropathology and Neuropsychological Performance
Sufficient numbers of NFTs and SPs are necessary for a diagnosis of AD, and
research indicates that these lesions correlate with the presence of dementia (Goedert,
Sisodia & Price, 1991). Clinical-pathological (CP) studies seek to understand both the
clinical and biological significance of AD neuropathology and are therefore
indispensable for assessing the clinical significance of amyloid plaques and
neurofibrillary pathology. Although CP studies have been active for several decades, the
relationship between AD neuropathology and the severity of cognitive decline still
remains unclear (Nelson, Braak & Markesbery, 2009). Some studies report that plaques
correlate highly with dementia.

For example, Dickson and colleagues

(1995)

demonstrated a correlation between cortical plaques and clinical symptoms of AD, as
measured by the Blessed Test of Information, Concentration and Memory (BICM). On
the contrary, others report that neurofibrillary tangles, and not plaques, correlate with
cognitive impairments. For instance, in an investigation of 10 AD patients, dementia
severity, as assessed by the Blessed Dementia Scale (BDS) was related to the number of
NFTs in the neocortex, yet there was no relationship between the BDS and the presence
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of SPs in the same brain region (Arriagada, Growdon, Hedley-Whyte & Hyman, 1992).
Over the years, the divergent outcomes of CP studies present a complicated
disease process that has resulted in varied, yet defensible, scientific positions. Although
disagreement persists, most of the recent literature asserts that plaques correlate poorly
with cognitive status, whereas NFTs seem to correlate more reliably with the clinical
manifestations of AD (Gunten, et. al, 2006). However, it is important to note that these
recent observations do not necessarily indicate an insignificant role of amyloid plaques
in AD. According to the amyloid cascade hypothesis, the disease process begins with
the deposition of amyloid beta protein (AbetaP), the main component of plaques, which
then leads to the formation of neurofibrillary tangles, cell loss, vascular damage and
dementia (Hardy & Selkoe, 2002).

However, this hypothesis has recently been called

into question, partially based on data indicating the presence of amyloid in nondemented brains (Swerdlow & Khan, 2009). The mitochondrial cascade hypothesis
asserts that the underlying cause of AD is early mitochondrial dysfunction and oxidative
stress, which subsequently initiates neuropathological changes (Young & Bennett,
2010). Most likely plaques are somehow related to the disease process, yet the quantity
of this lesion may not be a useful gauge when evaluating the cognitive status of elderly
individuals (Hyman, 1998).
Neuropathology in Centenarians
It is a well-documented phenomenon that the brains of older individuals contain
greater numbers of AD related neuropathology, relative to their younger counterparts.
These findings, considered concurrently with the rising rates of dementia with age, have
contributed to the prevailing theory that AD-type lesions are related to clinical symptoms
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of dementia (Double et al 1996). In fact, several quantitative CP correlation studies have
supported this theory, identifying an association between neuropathological markers of
AD and dementia severity.

However, the bulk of these investigations have been

conducted with individuals dying in their seventh through ninth decade (Haroutunian et
al., 2008). Currently, the literature reflects a paucity of neuropathological investigations
of patients older than 95; the few studies that have included the oldest-old provide
evidence that the brains of these individuals may be unique, making existing
neuropathological severity classification standards potentially less applicable to this
population.
The New England Centenarian Study, using a sample of 14 centenarians with
both the presence and absence AD, compared neuropsychological assessments with
postmortem brain investigations.

Although relatively clear CP associations were

reported for 8 out of the 14 subjects, with the extent of AD pathology positively
correlating with cognitive deficits, results for the remaining 6 subjects were enigmatic.
Some subjects had clinical histories of dementia but had no neuropathological evidence
of AD, while other subjects had no cognitive impairment despite having substantial
neuropathological disease burden. The results led the authors to conclude that dementia
was not necessarily an inevitable consequence of advanced age and that AD pathology
was not the only significant contributor of cognitive impairments in centenarians (Silver,
Newell, Brady, Hedley-White & Perls, 2001).

In another cohort-based study of

demented individuals ranging from 70 to 100, clinical manifestations of dementia and
underlying neuropathological findings varied with age. An association between NFT
count and dementia severity was observed. However, this relationship declined with
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increasing age (Savva, et al., 2009). Another investigation found that older individuals
with dementia had fewer AD pathological features at death compared to younger
individuals with dementia; there was no relationship between dementia severity and
neuropathological markers of AD in persons over 96 years of age.

These authors

concluded that neuropathological markers of AD were associated with dementia in the
youngest-old, but not in the oldest-old. (Prohovink, Perl, Davis, Libow, Lesser &
Haroutunian, 2006).
Present Study Summary
Given the preceding review, the lack of consensus between the various
neuropathological severity grading protocols used in post-mortem studies of AD may
result in inconsistent diagnoses of AD, particularly in extreme old age. In addition,
cognitively intact persons may also meet neuropathological criteria for AD, raising
questions regarding the nature of the relationship between cognitive functioning and
neuropathological burden in late life.
relationships in the oldest old.

Finally, few studies have investigated these

Existing studies of this select group of persons of

“extreme age” suggest the possibility of a different relationship between cognition and
neuropathology in these successful survivors. This study will focus on comparing and
contrasting similarities and differences among four different neuropathological grading
protocols in a sample of persons aged 98 years and older. Relationships between these
grading scales and neuropathological severity will be explored.
Method
Participants
Participants (N = 50) in this study were drawn from the Georgia Centenarian
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Study (GCS), which included 244 community-dwelling and institutionalized
centenarians and near-centenarians (M age = 100.6 years, SD = 2.04 years, range = 98108 years of age). This population-based sample was randomly selected from a 44
county catchment area in northern Georgia. Potential participants were identified from a
random sample of all nursing homes, assisted living facilities, and older individuals
residing in the community using voters’ registration records and random digit dialing.
The majority of participants (73.4%) had no more than a high school education; 15.6%
had a college degree. In terms of living arrangement, 37.3% of the centenarians lived in
their private home or apartment, 19.7% lived in assisted living facilities, and 43%
resided in skilled nursing facilities. Most centenarians (71.8%) reported that their health
was either good or excellent. The average Mini-Mental State Examination (MMSE;
Folstein, Folstein, & McHugh, 1975) score of the participants was M = 16.2 (SD = 8.81).
The sample was largely female (85%). Participant ethnicity composition was 79%
Caucasian and 21% African American. Depending on the number of sessions completed
(total of four), participants were compensated up to $600 for their involvement. For a
more comprehensive explanation of the data collection procedures used in the GCS, see
(Poon, et al., 2007).
Of the 50 participants who came to autopsy, there were six (12%) males and 44
(88%) females. A total of six cases (12%) were African American, and 88% were
Caucasian. A cross-tabulation of sex and race indicates that 12% of cases were African
American females, 12% were Caucasian males, and 76% were Caucasian females. The
mean age was 100.84 (SD=2.2 years, range=98 to 106 years), and the mean MMSE score
was 15.8 (SD=9.3, range=0 to 29). Again, most participants had no more than a high
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school education (77%), while 15% were college graduates. The mean number of years
of education was 9.3 years (SD=5.8 years, range=0 to 17 years).
Neuropathological materials and methods
Approximately 30% of the overall study participants agreed to donate their brains
for postmortem neuropathological investigation. All participants were autopsied by
William R. Markesbery at the University of Kentucky.

Dr. Markesbery quantified

neuropathological markers from the brain regions necessary in order to make diagnoses
according to Khachaturian, CERAD, NIA-R and Braak and Braak criteria.
Instruments
The instruments used in this study were part of a larger neuropsychological
evaluation administered to participants over two two-hour sessions. Each participant
participated in up to four total two-hour sessions, which also included blood chemistry
analysis, a physical examination, and administration of personality questionnaires and
measures of social and economic resources. Participants were typically tested in their
place of residence (private home, personal care home, or skilled nursing facility).
General cognitive ability. The MMSE (Folstein et al., 1975) is a wellestablished measure that contains 30 items that assess orientation, memory,
concentration, language and visual skills. Because of its brevity, reliability, and validity,
the MMSE is commonly used to assess general cognitive ability among older adults.
Research on community dwelling older adults suggests moderate internal consistency (α
= .62) in a normal sample and high internal consistency (α = .81) in a sample with
Alzheimer’s disease (Tombaugh, McDowell, Kristjansson, & Hubley, 1996).
Executive functioning. The Behavioral Dyscontrol Scale (BDS; Grigsby &
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Kaye, 1996) assesses motor-dependent executive functioning skills. This nine-item scale
evaluates ability to perform bilateral alternating movements, motor inhibition, letternumber sequencing, replication of body postures and gestures, and insight into
performance. BDS scores have demonstrated high internal consistency in geriatric
inpatients and outpatients (Grigsby, Kaye & Robbins, 1992).
Memory. The Fuld Object Memory Evaluation (FOME; Fuld, 1981) was
developed for testing memory in the elderly, and it has been standardized on nursing
home residents. Ten common objects are presented in a black cloth bag (e.g., bottle, ball,
key), and the examinee is instructed to identify each of the objects by touch. Afterwards,
the examinee is told to remove the object from the bag and to identify the object after
seeing it. Next, the objects are placed back in the bag and the examinee is distracted by a
verbal fluency task. Following the distraction task, there is a second recall period,
during which the examinee is asked to recall the objects from the bag. There are four
more subsequent recall trials, in which the examinee is reminded of the omitted items at
the end of each recall period and then is distracted using verbal tasks. Each examinee’s
storage efficiency (number of items recalled after each distracter task) and retrieval
efficiency (number of words recalled on each trial) is assessed.
The FOME has been used in a number of studies of aging and dementia, and
excellent reliability and normative data are available for the FOME, when given to older
adults (Fuld, 1981; Marcopulos, McLain, & Giuliano, 1997). For example, using a
sample of 96 elderly Chinese participants, test-retest reliability was found to be 0.92 and
parallel-form reliability was found to be 0.96 (Chung & Ho 2009). In a sample of 104
African Americans and European-Americans, with and without dementia, it was
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demonstrated that the FOME was able to accurately distinguish those with dementia
98.3% of the time (Mast, Fitzgerald, Steinberg, MacNeill, & Lichtenberg, 2001).
For the purposes of this study, the recognition, recall, and retention estimate
(five-minute delayed recall and recognition) will be examined, as these measures provide
a comprehensive index of retention of newly learned material when using the FOME.
Also, the sum of items consistently recalled over trials (repeated retrieval) will be
included in the analyses, which provide an index of immediate learning over trials and
demonstrates how efficiently information is retrieved from memory during new learning.
Instrumental activities of daily living. Performance-based measures of
instrumental activities of daily living were assessed using a modified version of the
Direct Assessment of Functional Status (DAFS; Loewnstein et al., 1989; Loewenstein,
Rubert, Arguelles, & Duara, 1995; Loewenstein et al., 1992). Importantly, the DAFS is a
clinician-rated scale, which helps to eliminate the bias and inaccuracies inherent in proxy
or self-report measures (Miller, et al., 2010). In order to administer the DAFS, the
clinician asks the patient to perform tasks related to time orientation, communication,
transportation, preparing for grocery shopping, financial skills, grocery shopping,
dressing and grooming, and eating. The measure assesses both BADLs and IADLs.
However, only IADL tasks were examined in the current study, given their strong
relationship with cognitive functioning.

Furthermore, reading transportation signs,

preparing for grocery shopping, and grocery shopping tasks of the DAFS IADL items
were omitted given their physical demands and low likelihood that centenarian
participants performed these tasks with any regularity. Each DAFS IADL task was
scored according to objective criteria that evaluated the number of correct steps
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performed for each task, or the number of correct responses given for a particular task.
The IADL score was calculated by summing the time orientation, communication, and
financial skills scales (possible range = 0-58 points, higher scores represent higher
functional status). The DAFS has been used with older adults with Alzheimer’s disease
(Lowenstein et al., 1989) and in community-dwelling samples (Mitchell & Miller, 2008).
DAFS scores also have demonstrated inter-rater reliabilities ranging from .91 to 1.0 and
three to seven week test-retest reliabilities of .92 to 1.0 in healthy older adults (.72 to .91
in older adults with memory disorders) across summary functional scales (Lowenstein et
al., 1989).

Anticipated Problems and Proposed Solutions
Several study limitations were anticipated. Ideally, each subject would have had
an evaluation at the same time point, near the time of death, to relate cognitive
impairment

to

neuropathology

found

at

autopsy.

However,

obtaining

neuropsychological test data shortly before death was not always possible, creating some
variation among the sample regarding the most recent neuropsychological evaluation and
the time of death. Therefore, the relationship between the amount of time between
neuropsychological testing and postmortem brain analysis was examined.
It is well established that within an elderly sample, there are many possible
confounding disease processes contributing to cognitive impairment, including
cerebrovascular disease (CVD), dementia with Lewy bodies, argyrophilic grain disease,
and hippocampal sclerosis (Nelson et al., 2007). However, excluding brains with
concurrent pathology would not necessarily enhance the understanding of the currently
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used diagnostic systems, especially in a sample of the oldest old.
It is recognized that a small percentage of the larger sample agreed to brain
donation, potentially resulting in a selection bias.

Because the sample is

disproportionately female and Caucasian, the small cell sizes for the combination of
gender and ethnicity in this study precludes subgroup analysis of gender and ethnic
factors. However, we compared the demographic characteristics of the larger sample to
the demographic characteristics of the participants used in our study. These comparisons
allowed us to identify any possible sources of demographic biases.
Finally, this study measures cognitive status, utilizing a set of measures selected
by the researchers for specific reason, such that each measure is related to impairments
commonly seen in patients with AD. Therefore, it is possible that there are other
relevant domains of cognitive functioning not investigated with the measures used in this
study. However, given the small sample size, it was necessary to restrict the number of
DVs to a reasonable size.
Data Analysis
Data for this study was analyzed using Stata Statistical Software: Release 10
(StataCorp., 2007). Neuropsychological tests were screened for univariate outliers by
inspecting influence plots and extreme values. In addition, for all regression analyses,
regression diagnostics were used to identify overly influential observations. Values were
considered for removal based on standardized residuals (if <-3 or >3), DFBetas (if >.28),
and Cook’s Distance (if >.08). In order to check for multicollinearity, the variance
inflation factor (VIF) was examined, with values greater than ten indicating a
problematic linear relationship. Overall, no data points were removed from the final
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analyses.
Specific Aim 1 was analyzed using a series of McNemar-Bowker tests for
correlated proportions.

These analyses showed the extent to which each pair of

neuropathological criteria, as applied to each person, differed with respect to their
severity classifications. This statistical procedure also indicated where classification
errors were most frequent (e.g., does one criteria over-predict severity or under-predict
severity relative to another set of criteria). When comparisons were being made between
two sets of neuropathological criteria with unequal numbers of severity levels, levels
were collapsed appropriately to allow for equivalent comparisons. Both NIA-R criteria
and CERAD criteria have three severity levels, Braak and Braak criteria has six severity
levels, and Khachaturian criteria has two severity levels. When comparing to NIA-R and
CERAD to Braak and Braak, Braak and Braak stages I and II, III and IV, and V and VI
were combined in order to establish three severity levels. Khachaturian criteria has a
dichotomous classification: either AD is present or absent. In order to establish two
levels, Braak and Braak stages I and II were collapsed to represent the absence of AD;
stages III, IV, V, and VI were collapsed to represent the presence of AD.

When

comparing Khachaturian to both NIA-R and CERAD, the severity level indicating the
least amount of neuropathology was used to represent the absence of AD, and the
reaming two levels were collapsed to represent the presence of AD. Because each set of
neuropathological criteria was ordinal in nature, Spearman rho rank-ordered correlations
were computed to determine the extent of agreement between each pair of criteria.
Specific Aim 2.1 was analyzed using hierarchical multiple regression analyses
separately

for

each

neuropathological

grading

system.

Scores

for

each

24
neuropsychological test served as the dependent variables.

After entering age,

education, and gender, dummy coded values for the severity levels for a given
neuropathological grading system were entered to determine the proportion of variance
accounted for by that system. These analyses indicated to what extent neuropathological
severity could predict neuropsychological test performance. Dummy coding was used,
with the reference group being the neuropathological classification level indicating the
least amount of pathological burden. It was anticipated that some classification systems
would be better at predicting impairment, thus these systems would yield significant
differences between levels. The R2 change was examined to provide an indication of how
much each neuropathological severity grading system contributes to the variation in the
neuropsychological measures.

Greater R2 change provided evidence that a

neuropsychological measure is sensitive to neuropathological burden.
Specific Aim 2.2 was analyzed using the Georgia Centenarian Database to
establish normative data for the neuropsychological measures under study.

After

removing the 50 participants included in the current study, data from the remaining 194
centenarians was used to calculate the mean performance on each neuropsychological
measure.

Subsequently, impaired performance was defined as one standard deviation

below the mean and intact performance was defined as above one standard deviation
below the mean. The variables for the FOME Total Recall, Total Recognition, and
Repeated Retrieval Indices were not normally distributed, and the standard deviation
exceeded the mean. Therefore, these measures were excluded from the analysis. Using
a Fisher’s Exact Test, the proportions of intact and impaired scores on the BDS, the
MMSE, the DAFS IADL and the FOME Retention Estimate Index were compared
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across AD disease severity rating, using NIA-R criteria.
Results
Preliminary Analysis
Since participants included in our study were not randomly assigned to brain
donation, we compared the demographic characteristics of the larger sample with the
participants included in the present study. The participants that agreed to brain donation
had an average age of approximately 101 years (M age = 100.8 years, SD = 2.15 years);
approximately nine years of education; (M education=9.26 years, SD=5.84 years); and an
average MMSE score of 15.8 (SD=9.34). Out of the 50 participants included in the
present study, 12% were male and 12% were African-American. The remaining 194
centenarians had an average age of 100.5 years (M age = 100.58 years, SD = 2.01 years);
approximately 11 years of education; (M education=10.67 years, SD=3.74 years); and an
average MMSE score of 16.30 (SD =8.69). 16% of these participants were male and 24%
were African-American. Independent sample t-tests were used to determine whether
significant differences existed between the two groups. There were no significant
differences in age t(72.6) = .89, p=.18; years of education t(59.73)= -1.32, p=.95; and
MMSE scores t(53.11)=-.37, p=.64. A chi-square test indicated that the two groups did
not differ in terms of race χ2 (1)=2.86, p=.09 or gender χ2(1)=.46, p=.50.
There was variation in our sample related to the amount of time that had elapsed
between each participant’s neuropsychological evaluation and their time of death. In
order to address this issue, we investigated the correlation between the number of days
the participant lived after completing the neuropsychological evaluation (days) and
neuropsychological test performance. The number of days between testing and death was
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significantly related to BDS (r=.51, p<.05); DAFS IADL (r=.43, p<.05); FOME
Retention Estimate Index (r=.29, p<.05); and the MMSE (r=.38, p<.05). Days was not
related to the FOME Total Recognition Index (r=.16, p=.31); FOME Total Recall Index
(r=.25, p=.07); or the FOME Repeated Retrieval Index (r=.18, p=.20). Although the
number of days prior to death was related to most of the neuropsychological measures,
this variable was not significantly related to the any of neuropathological criteria under
study.
Specific Aim 1
The goal of this aim was to determine whether the four different
neuropathological assessment protocols yielded conflicting or consistent diagnostic
information regarding AD severity.

NIA-R criteria severity ratings departed

significantly from symmetry when contrasted with the severity ratings of both CERAD
(p=.03) and Khachaturian criteria (p<.01). When compared to NIA-R, CERAD overpredicted neuropathological severity. The greatest disagreement between classifications
occurred between CERAD “probable” AD and NIA-R “low likelihood” of AD. When
compared to NIA-R, Khachaturian also over-predicted neuropathological severity. The
greatest disagreement between classifications occurred between the Khachaturian
diagnosis of AD and NIA-R “low likelihood” of AD. There was symmetry among the
remaining comparisons: Braak & Braak and NIA-R (p=.25), Braak & Braak and
CERAD (p=.06), Braak & Braak and Khachaturian (p=.55), Khachaturian and CERAD
(p=.45). Spearman rho rank-order correlations indicated that there were significant
associations amongst all criteria assessed: Khachaturian and Braak and Braak (rho=.63,
p<.01); Khachaturian and CERAD (rho=.64, p<.01); Khachaturian and NIA-R (rho=.73,
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p<.01); NIA-R and CERAD (rho=.74, p<.01); NIA-R and Braak and Braak (rho=.93,
p<.01); Braak and Braak and CERAD (rho=.59, p<.01). In summary, there was general
agreement among most of the neuropathological grading criteria. However the NIA-R
criteria differed significantly from the CERAD and the Khachaturian criteria, and a nonsignificant trend was observed when the Braak and Braak and CERAD criteria were
compared.
Specific Aim 2
The goal of this aim was to investigate the relationship between disease
progression and the extent and type of cognitive and functional impairment in a sample
of centenarians.
Specific Aim 2.1. This aim hypothesized that severity grading criteria from
diagnostic protocols that rely on NFTs as a neuropathological indicator of AD diagnosis
would be significantly related to cognitive impairment, whereas severity gradings from
protocols that emphasize SPs would not be related to cognitive impairment. After
controlling for demographic variables, NIA-R criteria predicted performance on the
MMSE (R2 change=.18, F(2,32)=4.86, p<.05) and the FOME Retention Estimate Index
(R2 change =.18, F(2,32)=5.48, p<.01), the FOME Total Recall Index (R2 change =.15,
F(2,32)=3.51, p<.05), and the FOME Repeated Retrieval Index (R2 change =.20,
F(2,32)=4.86, p<.05).

A similar pattern was found with the CERAD, which also

predicted performance on the MMSE (R2 change=.18, F(2,32)=4.86, p<.05) and the
FOME Retention Estimate Index (R2 change =.15, F(2,32)=4.25, p<.05), the FOME
Total Recall Index (R2 change =.18, F(2,32)=4.48, p<.05), and the FOME Repeated
Retrieval Index (R2 change =.19, F(2,32)=4.48, p<.05).

Braak and Braak criteria
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predicted performance on the MMSE (R2 change=.14, F(2,32)=3.62, p<.05) and the
FOME Retention Estimate Index (R2 change =.13, F(2,32)=3.67, p<.05). Khachaturian
criteria did not predict performance on any of the neuropsychological measures assessed.
Specific Aim 2.2. In this aim, we hypothesized that different stages of disease
progression will yield distinct neuropsychological impairments. After removing the 50
participants who agreed to brain donation, we established normative data for the
neuropsychological measures under study using the remaining 194 Centenarians (see
Table 4). Impaired performance was defined as one standard deviation below the mean
and intact performance was defined as above one standard deviation below the mean. A
Fisher’s Exact Test of the relationship between NIA-R severity rating and presence or
absence

of

neuropsychological

impairment

was

not

significant

for

any

neuropsychological or functional measure. However, there was a non-significant trend
for the FOME Retention Estimate (p=.09, Cramer’s V=.40), such that those classified as
“impaired” on this index of the FOME had more severe AD neuropathology, with the
greatest proportion of impaired individuals classified as having a “high likelihood” of
AD. Additionally, those classified as “intact” had less severe AD neuropathology, with
the greatest proportion of intact individuals classified as having a “low likelihood” of
AD.
Discussion
We found that the NIA-R criteria differed significantly from both the CERAD
and Khachaturian criteria.

The remaining comparisons did not yield significant

differences. Spearman’s rho correlations ranged from .93 to .59.

The strongest

association was found between NIA-R and Braak and Braak, and the weakest association
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was found between CERAD and Braak and Braak. These findings are consistent with
recent research from Brunnstrom and Englund (2011), who compared four sets of
neuropathological criteria, including: Braak and Braak, CERAD, NIA-R and the PolyPathology Alzheimer’s Disease Assessment. Although these authors did not include
centenarians in their sample, they nevertheless reported “suboptimal” correlations
between the four sets of neuropathological criteria used for AD diagnosis in their study.
Our work, in conjunction with the aforementioned investigation, provides additional
evidence of disagreement among neuropathological diagnostic criteria. Therefore, the
criteria used by a neuropathologist can ultimately have a bearing on the quantification of
Alzheimer neuropathology and the subsequent diagnosis.
Although severity classifications based on NIA-R criteria were divergent from
the severity classifications based on CERAD criteria, our results indicate that these two
criteria both predict neuropsychological performance level on the MMSE and three
FOME indices (Recall, Retention, Repeated Retrieval). In contrast, Braak and Braak
criteria predicted performance on the MMSE and the FOME Retention Index, and
Khachaturian criteria did not predict performance on any of the measures assessed. The
observed overlap between NIA-R and CERAD was not expected. Clinico-pathological
studies have provided more support for the detrimental impact of NFTs on
neuropsychological test performance, compared to NPs. In general, correlations between
ante-mortem cognitive dysfunction and the quantity of NPs found in the brain postmortem are weak (Nelson, Kukull, & Frosch, 2010). It is not uncommon for individuals
with considerable amounts of NPs to have no clinical signs of AD. For example, after
examining 1,672 brains, one study found that NPs were the most common disease
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process observed in the 242 participants who had intact cognition prior to death (Sonnen,
et al., 2007). As a consequence of the accumulated research evidence indicating a
limited relationship between NPs and clinical symptoms of AD, neuropathologists are
particularly hesitant to interpret amyloid deposition in the brain as a harbinger for
diagnosis (Giaccone, et al., 2011). Therefore, it was expected that Braak and Braak
criteria would best predict neuropsychological test performance. However, the
similarities between NIA-R criteria and CERAD criteria raise some questions regarding
the significance of NFTs in the oldest old. Could the presence of NPs play a more
detrimental role in memory as humans advance to the extremes of old age? Alternately,
could the relationship between NFTs and cognition be less pronounced in centenarians,
compared to the younger old? The few studies that have included the oldest old have
provided some support for an age dependent relationship between cognition and
neuropathology. For example, Savva et al. (2009) reported that the relationship between
NFTs and dementia status in older participants was weaker, when compared to younger
participants. Similarly, (Dolan, et al., 2010) conducted postmortem brain examinations
in 209 elderly individuals and found that NFTs were associated with more cognitive
impairment among the younger participants, but older participants with equal numbers of
NFTs had fewer clinical signs of dementia. Because there is evidence that suggests that
NFTs become less influential with age, it may be possible that the accumulation of NPs
then becomes more influential with age.

In order to refine the neuropathological

assessment of AD, the association between increasing age, NPs and NFTs deserves
further investigation.
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The unforeseen relationship between CERAD criteria and cognitive functioning
may also be supported by the “amyloid cascade hypothesis”, which posits that β-amyloid
is directly and indirectly responsible for the neurodegeneration observed in AD.
According to this theory, the accumulation of fibrillar β-amyloid plaques in the brain
eventually leads to neuronal dysfunction, neuronal death, and cognitive decline
(Khairallah & Kassem, 2011). It has been suggested that β-amyloid can collect near
synaptic terminals, damage the synapses, and eventually lead to the cognitive
impairment seen in patients diagnosed with AD (Reddy & Beal, 2008). In addition,
excess β-amyloid may interfere with mitochondrial function (Anandatheerthavarada,
Biswas, Robin, & Avadhani, 2003). Because the human brain requires energy to operate,
it is exceedingly sensitive to mitochondrial changes. Animal models have provided
evidence that mitochondrial dysfunction is associated with cognitive impairment, and it
is believed that these same mechanisms may account for the cognitive changes observed
in humans with AD (Hauptmann, et al., 2009). These results are consistent with our
findings, which suggest that accumulations of NPs may be significant, especially for
those that reach the extremes of old age. However, it is also possible that by simply
living a long life, one will invariably accumulate more β-amyloid and the subsequent
neuronal changes β-amyloid is known to produce. Therefore, additional research will be
necessary in order to elucidate the role of NPs and β-amyloid within the aging brain.
Contrary to expectations, our findings did not reveal a significant relationship
between NIA-R AD disease severity ratings and impaired neuropsychological test
performance. However, there was a non-significant trend for the FOME Retention
Estimate Index. This trend was not surprising considering that the hippocampus, which
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is required for memory formation, is affected during the earliest stages of the disease
(Bliss & Collingridge, 1993). According to our results, greater neuropathological burden
as classified by NIA-R criteria may be associated with greater memory impairment.
Limitations and Future Directions
One limitation of our study is that besides AD pathology, there are other brain
and vascular dysfunctions associated with increased age and decreased cognitive
performance. Therefore, it is difficult to determine if observed neuropsychological
weaknesses are directly associated with a specific AD type lesion.

For example,

according to some estimates, hippocampal sclerosis is found in approximately 26% of
the elderly population (Zarow, Sitzer, & Chui, 2008). Additionally, the vast majority of
brains at the extremes of age will reveal, at the very least, signs of an emerging vascular
disease. A recent investigation of 1,110 autopsied brains found that those participants
who lived beyond 95 years were more likely to have hippocampal sclerosis pathology,
and less likely to have AD pathology, as compared to younger participants. These
authors conjecture that the positive correlation between age and dementia may be best
explained by cerebrovascular pathology and hippocampal sclerosis, not by AD
neuropathology (Nelson, et al., 2011).
Another limitation of our study was the variability among our participants
regarding the amount of time that had elapsed between neuropsychological evaluation
and time of death. When examining this relationship, we found that days prior to death
was related to neuropsychological test performance, increasing the likelihood that days
prior to death would have an impact on our results. We found that for several of the
neuropsychological tests there was a significant association, such that the longer the
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participant lived after completing a neuropsychological evaluation, the better their
performance on cognitive and functional measures. This finding is consistent with the
“terminal decline hypothesis”, which suggests that factors that contribute to death may
also interfere with cognitive functioning in the years immediately proceeding death
(Kleemeier, 1962).

Studies have demonstrated that older adults experience an

accelerated decay in neuropsychological performance, which starts during the last three
and a half years of life (Wilson, Beck, Bienias, & Bennett, 2007). But, there is some
evidence to suggest that terminal decline is markedly different in centenarians. For
example, one study found that the functional impairment associated with terminal
decline began closer to the age of death in the oldest old, sparing cognitive abilities in
this population compared to the younger old (Hitt, Young-Xu, Silver, & Perls, 1999). In
addition, there is some evidence which implies that AD neuropathology may be linked to
the phenomenon of terminal decline; however, there is a paucity of studies that have
examined this relationship, making this theory tentative at best (Wilson, 2008). Future
investigations should employ longitudinal designs to explore the association between
AD neuropathology and terminal decline, in samples of the younger old and oldest old.
A more comprehensive examination of these relationships could enhance our
understanding of age-related cognitive changes associated with AD, which in turn could
enhance end-of-life care for aging individuals.
There is a growing body of literature that seeks to identify modifiable risk factors
of AD and research has indicated a possible relationship between diet and AD (Reynish,
Andrieu, Nourhashemi, & Vellas, 2001). For example, epidemiological studies show
evidence that serum cholesterol and saturated fats are related to an increased risk of AD,
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while omega-3 fatty acids and antioxidants are related to a decreased risk of AD (Morris,
2009). Although human studies that have examined the association between dietary
factors and AD have not included neuropathological data, recent research using
transgenic mouse models have examined AD neuropathology as it relates to diet and
nutrition (Mobbs, Yen, & Hof, 2007).

For instance, one study has indicated an

association between increased omega-3 intake and decreased in β-amyloid (Lim, et al.,
2005). Similarly, another study found that vitamin-E levels in mice were related to
reductions in β-amyloid accumulations in the brain (Sung, et al., 2004).

Since our

understanding of the association between diet and AD neuropathology comes largely
from animal models, future research should attempt to replicate animal findings using
human samples. In view of the fact that available medications are known to result in
minimal improvements, understanding the influence that diet may have on the
progression of AD could lead to the development of more effective interventions and
symptomatic relief (Kaduszkiewicz, Zimmermann, Beck-Bornholdt, & Van Den
Bussche, 2005). With animal models indicating a relationship between dietary changes
and β-amyloid reductions, taken with our current findings, dietary interventions may be
particularly important for those individuals who reach the extremes of old age.
Conclusions
In conclusion, our findings indicate that there are inconsistencies among the
available post-mortem diagnostic criteria for AD, such that diagnoses made with NIA-R
criteria may not be in agreement with diagnoses made with either CERAD or
Khachaturian criteria.

Further research focused on establishing a “gold standard”

neuropathological diagnosis of AD is needed. A shared lexicon would encourage more
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consistency among researchers, thereby enhancing collaboration and the dissemination
of valuable information. In addition, development of a gold standard should rely on
research that considers the way AD develops and is manifested throughout the lifespan.
Our results also indicated that NIA-R criteria and CERAD criteria were both able
to predict general cognitive status and memory performance. In addition, NIA-R and
CERAD criteria proved to be superior at predicting memory performance, as compared
to Khachaturian and Braak and Braak criteria.

This finding suggests that the

preponderance of evidence indicating a significant role of NFTs relative to NPs may be
related to the age of the participants under study.

In addition, we also found a non-

significant trend suggesting that that the FOME Retention Estimate might be sensitive to
increasing amounts of neuropathology.
The present study makes important contributions to the limited literature
addressing AD-type neuropathology in centenarians. Centenarians represent a unique
population that may provide valuable insights into the final stages of the progression of
AD. Therefore, to better understand this disease process, future research efforts should
continue to examine the consequences of AD neuropathology in individuals who live to
the extremes of old age.
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Table 1
Independent Variables Examined in the Present Study
Neuropathological

Levels

Comparisons for regression

None

No evidence of AD compared to Yes,

criteria
Katchaturian

evidence of AD
Braak & Braak

Stages I,II,III,IV,V,VI

Stage I and II
compared to stage III and IV and also
compared to V and VI

CERAD

Possible, probable or

Possible AD compared to probable AD

definite (after

and also compared to definite AD

integration of plaque
count and clinical
history of dementia)
NIA Regan

High, intermediate or

Low likelihood of AD compared to

low

intermediate likelihood of AD and also
to high likelihood of AD
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Table 2
Dependent Variables Examined in the Present Study
Neuropsychological Measure

Purpose

Score used

Mini Mental State Exam

General measure of cognitive

Total score

(MMSE)

status

Behavioral Dyscontrol Scale

Assessment of motor dependant

(BDS)

executive functioning skills

Fuld Object Memory

Measure of memory

Evaluation (FOME)

Total score

Repeated Retrieval
Index, Total Recall
Index, Total
Recognition Index,
Retention Estimate

Direct Assessment of

Assessment of the ability to

Instrumental

Functional Status (DAFS)

perform tasks necessary for

Activities of Daily

daily living

Living (IADL)

38
Table 3
Neuropathological Criteria
Neuropathological

Plaques

Tangles

Location

Levels

criteria
Katchaturian

Age adjusted

Necessary for

Neocortex

Yes or No

neocortical

AD diagnosis,

(frontal,

plaques (neuritic

only if patient

temporal and

and diffuse) per

is younger than parietal lobes)

unit

75

Not necessary

Assessment of

Braak & Braak

Inferotemporal

Stages

allocortex,

I,II,III,IV,

tangles, and

hippocampus,

V,VI

neuropil

neocortical

threads

association areas

Assessment of

Not necessary

Hippocampus,

Possible,

neuritic plaques,

for AD

amygdala, and

probable

using a scale

diagnosis

neocortex

or definite

Not necessary

A combination

High,

of CERAD and

intermedia

Braak & Braak

te or low

for AD diagnosis neurofibrillary

CERAD

from none to
frequent
NIA Reagan

Not necessary

for AD diagnosis for AD
diagnosis
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Table 4
Normative Data from the Georgia Centenarian Study
Measure

M

SD

n

Minimum

Maximum

-1 SD

BDS

8.23

6.50

183

0

19

1.73

MMSE

16.22

8.74

195

0

30

7.48

DAFS IADL

26.29

18.19

182

0

58

5.1

FOME

2.90

3.01

186

0

10

N/A

5.94

4.03

186

0

10

1.91

3.03

2.40

186

0

9

.63

6.03

7.53

197

0

30

N/A

Total Recall
FOME
Retention Est.
FOME
Total Recognition
FOME
Repeated Retrieval
Note: MMSE= Mini Mental State Exam, BDS=Behavioral Dyscontrol Scale, FOME=
Fuld Object Memory Evaluation, DAFS IADL=Direct Assessment of Functional Status
Instrumental Activities of Daily Living
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ABSTRACT
NEUROPATHOLOGICAL DIAGNOSIS OF ALZHEIMER’S DISEASE: THE
RELATIONSHIP BETWEEN POSTMORTEM ASSESSMENT, COGNITIVE
FUNCTION AND FUNCTIONAL STATUS IN CENTENARIANS.
by
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Several sets of neuropathological criteria have been used for the postmortem
diagnosis of Alzheimer's Disease (AD), but few studies have examined these criteria in
the oldest old. For this study, we examined a sample of centenarians, all of whom
received AD assessments using four different neuropathological criteria: Khachaturian,
Braak and Braak, CERAD, and NIA-R. Findings indicate that NIA-R criteria differed
significantly from CERAD and Khachaturian criteria. In addition, NIA-R and CERAD
criteria predicted performance on the MMSE and three FOME indices; Braak and Braak
criteria predicted performance on the MMSE and one FOME index. Finally, we
examined the relationship between NIA-R severity rating and the presence or absence of
neuropsychological impairment. We found that neuropathological severity was not
significantly related to impairment for any neuropsychological or functional measure.
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